Company news

Revive Therapeutics Ltd. news in 2025

Revive Therapeutics Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

December 15, 2025

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

September 19, 2025

Revive Therapeutics Announces Extension of Proposed Private Placement

September 5, 2025

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

August 11, 2025

Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

July 30, 2025

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

July 8, 2025

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

June 26, 2025

Revive Therapeutics Advances with Next-Generation Bucillamine Development

June 4, 2025

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

May 12, 2025

Revive Therapeutics Announces Proposed Shares for Debt Transaction

April 21, 2025

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

April 10, 2025

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

April 1, 2025

Revive Therapeutics Announces Results of Annual Shareholder Meeting

March 19, 2025

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

March 3, 2025

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

February 3, 2025

Decks in 2025